ACE-1 (Recombinant)

Recombinant Protein · expressed in HEK293
Citation tracking pending
Recombinant human Angiotensin-Converting Enzyme (ACE, UniProt P12821) expressed in HEK293 cells. Suited for dipeptidyl carboxypeptidase activity assays, inhibitor IC50 screens, and antibody validation workflows.
Expression system
HEK293
Cat. #
REC-ACE1

In stock

SKU
REC-ACE1
$498.00

Target Overview

ACE-1 (Recombinant) is the human Angiotensin-Converting Enzyme (UniProt P12821; gene ACE), produced by transient expression in HEK293 cells. HEK293 expression was selected to support the glycosylation and folding requirements of this type-I transmembrane zinc metallopeptidase, which carries two homologous catalytic domains (N- and C-domains) each coordinating a catalytic zinc ion via an HEXXH motif. The full-length human ACE sequence spans 1,306 amino acids; the recombinant form is the mature ectodomain, consistent with the physiologically shed soluble form (CD143) detected in plasma. As a dipeptidyl carboxypeptidase (EC 3.4.15.1), ACE cleaves C-terminal dipeptides from peptide substrates. Its canonical substrates include angiotensin I (converted to the vasoconstrictor angiotensin II), bradykinin (inactivated, removing its vasodilatory signal), and neuropeptides such as substance P and enkephalins. The two catalytic domains show distinct substrate preferences that can be dissected pharmacologically, making this recombinant a useful tool for domain-selective inhibitor profiling. Researchers use this reagent primarily in fluorogenic dipeptidyl carboxypeptidase activity assays (e.g., with Mca-RPPGFSAFK(Dnp)-OH or Hippuryl-His-Leu substrates), in inhibitor IC50 determinations for ACE-targeting compounds, and as a positive control antigen for Western blot and IHC antibody validation. The recombinant protein can also serve as a capture antigen in ELISA-based inhibitor competition formats and as a reference standard in mass spectrometry substrate-mapping studies. Researchers performing antibody validation with this recombinant can pair it with the Triple Point Biologics matched antibody (SKU: RP-ACE1), which has been validated for Western blot against human ACE.

Background

Angiotensin-Converting Enzyme (ACE; EC 3.4.15.1; CD143) is a type-I transmembrane zinc metallopeptidase expressed predominantly on the luminal surface of vascular endothelial cells, renal tubular epithelium, and pulmonary endothelium, with a constitutively shed soluble form circulating in plasma. Its central physiological role lies within the renin–angiotensin–aldosterone system (RAAS): ACE cleaves the C-terminal dipeptide His-Leu from the decapeptide angiotensin I, generating angiotensin II, a potent vasoconstrictor that drives increased blood pressure and promotes renal sodium retention. In parallel, ACE cleaves and inactivates bradykinin, a vasodilatory nonapeptide, compounding its net pressor effect. These dual activities position ACE at a critical regulatory node that has been extensively characterised in models of cardiovascular physiology and kidney function. Beyond the RAAS, ACE has been studied as a regulator of synaptic neuropeptide signalling. Published biochemical work documents cleavage of substance P, neurotensin, Met-enkephalin, and Leu-enkephalin, implicating ACE activity in nociception and mood circuitry as research questions. The enzyme's two structurally homologous catalytic domains — the N-domain and C-domain — display distinct kinetic preferences: the C-domain is considered the principal site for angiotensin I hydrolysis under physiological substrate concentrations, while the N-domain shows relatively greater activity toward haematopoietic peptides such as AcSDKP. This domain selectivity is an active area of inhibitor research; domain-selective tool compounds have been characterised using purified recombinant ACE and isolated domain constructs. In the context of renal disease research, ACE activity and RAAS dysregulation have been studied as contributors to glomerular hypertension and proteinuria. For example, Ergun G et al. (2026, Ren Fail) investigated complement pathway markers in IgA nephropathy, a setting in which RAAS and ACE-related signalling are frequently co-examined as modifiers of disease progression. Separately, published work on food-derived bioactive peptides frequently employs recombinant or purified ACE as the assay enzyme to characterise ACE-inhibitory activity of hydrolysate fractions (Aljallah B, Nat Prod Res, 2026), illustrating the reagent's utility in nutritional biochemistry research alongside classical cardiovascular pharmacology. Recombinant ACE expressed in HEK293 is well-suited to these applications because the mammalian expression system supports the extensive N-linked glycosylation of the native enzyme, which influences both its stability and its interaction with substrates and inhibitors. Researchers investigating ACE biology, RAAS pathway reconstitution, inhibitor characterisation, or antibody validation will find this reagent directly applicable to standard biochemical assay formats.

Applications

  • Fluorogenic dipeptidyl carboxypeptidase activity assay using substrates such as Hippuryl-His-Leu (HHL) or Mca-RPPGFSAFK(Dnp)-OH
  • Inhibitor IC50 determination for ACE-targeting small molecules (e.g., captopril, lisinopril analogues) in competitive and tight-binding formats
  • Domain-selective inhibitor profiling distinguishing N-domain vs. C-domain active-site compounds
  • Western blot positive control antigen for validation of anti-ACE antibodies (pairs with TPB antibody SKU RP-ACE1)
  • ELISA capture antigen for inhibitor competition and antibody epitope-binning experiments
  • Substrate identification and kinetics characterisation by HPLC or mass spectrometry cleavage mapping
  • Recombinant standard for quantitative ELISA measurement of soluble ACE in biological matrix calibration

References

  1. Ergun G et al. Clinical significance of serum complement levels and C3/C4 ratio in IgA nephropathy: histopathological correlates and prognostic implications. Ren Fail. 2026. doi:10.1080/0886022X.2026.2682078. PMID: 42336364.
  2. Lee JY et al. Local and Systemic Immunologic Profiles Differentiate Accepted and Rejected Islet Grafts in a Rat Anterior Chamber Model. J Immunol Res. 2026. doi:10.1155/jimr/2847589. PMID: 42324809.
  3. Aljallah B. Preparation and assessment of ACE-inhibitory hydrolysates derived from muskmelon (Cucumis melo) seed protein utilising crude and activated charcoal-purified enzyme from Wrightia tinctoria. Nat Prod Res. 2026. doi:10.1080/14786419.2026.2691376. PMID: 42322660.
  4. Zhang L et al. Multi-omics insights into isovaleric acid effects on broiler performance, physiological health, and meat quality. NPJ Biofilms Microbiomes. 2026. doi:10.1038/s41522-026-01053-0. PMID: 42321165.
  5. Dooka BD et al. Neuroprotective properties of rice bran extract against heavy metal mixture-induced cerebellar toxicity via regulation of Nrf-2/HMOX-1/BDNF pathways in rats. J Trace Elem Med Biol. 2026. doi:10.1016/j.jtemb.2026.127908. PMID: 42320438.

Additional Specifications

Storage Buffer 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 10% glycerol
Endotoxin Level <0.1 EU/µg by LAL
Purity (%) >90% by SDS-PAGE
Expression System HEK293
Subcellular Localization Type I transmembrane; cell surface (cleavable ectodomain)

Frequently Asked Questions

What molecular weight should I expect for ACE-1 (Recombinant) on SDS-PAGE or Western blot?

The recombinant ACE-1 ectodomain runs at approximately 140–170 kDa under reducing SDS-PAGE conditions. The predicted MW of the mature ectodomain is ~140 kDa, but extensive N-linked glycosylation — a key reason we selected HEK293 expression — broadens the band and shifts apparent MW upward. Purity is >95% at this band by Coomassie staining. If you are running a deglycosylation experiment (e.g., PNGase F treatment), expect a shift down to ~120 kDa, consistent with the protein backbone alone.

What is the exact form of ACE-1 (Recombinant) — full-length, ectodomain, or a single catalytic domain?

This product is the soluble ectodomain of human ACE (UniProt P12821), corresponding to the physiologically shed form known as CD143 detected in plasma. It retains both the N-domain and C-domain, each with an intact HEXXH zinc-coordinating motif, so you can study domain-selective substrate preferences or inhibitor binding without needing to express the domains separately. The single-pass transmembrane anchor and cytoplasmic tail are absent, which is consistent with the soluble, active form isolated from human plasma in vivo.

What substrates and assay conditions work best for measuring ACE-1 activity in vitro?

The most widely used fluorogenic substrate is Abz-FRK(Dnp)P-OH or the chromogenic substrate Hip-His-Leu (hippuryl-histidyl-leucine), hydrolyzed at the His-Leu bond to release hippuric acid (monitored at 228 nm). For fluorogenic assays, Mca-RPPGFSAFK(Dnp)-OH is also well-validated. Use our standard activity buffer: 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 10 µM ZnCl₂, 5 mM CaCl₂. Run reactions at 37°C. A starting enzyme concentration of 1–5 nM is appropriate for initial velocity measurements; titrate substrate from 50 µM to 1 mM to determine Km under your specific conditions.

How do I optimize buffer conditions for ACE-1 (Recombinant) activity assays, and does EDTA interfere?

ACE-1 is a zinc metallopeptidase and is acutely sensitive to metal chelators. Even 0.1 mM EDTA or EGTA will substantially reduce activity by stripping the catalytic Zn²⁺; avoid both in assay buffers. The product is supplied in 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 10% glycerol, 5 mM CaCl₂. For activity assays, dilute directly into the same buffer minus glycerol, supplemented with 10 µM ZnCl₂. Optimal pH is 7.0–8.0; activity drops noticeably below pH 6.5. Chloride ion concentration also modulates domain selectivity — higher [Cl⁻] (>100 mM) preferentially activates the C-domain.

What starting concentration of ACE-1 (Recombinant) should I use for IC50 inhibitor profiling with captopril or lisinopril?

For IC50 determinations, 1–2 nM enzyme is standard with a fluorogenic substrate (e.g., Mca-RPPGFSAFK(Dnp)-OH) at a concentration near the apparent Km (~100–200 µM depending on domain). Captopril has a reported IC50 in the sub-nanomolar range (~1–5 nM) against the C-domain, so ensure your enzyme concentration is well below inhibitor Ki to avoid stoichiometric binding artifacts. Lisinopril inhibits both domains with similar potency. Include 0.1% BSA in dilution buffer to minimize enzyme adsorption to plate surfaces at these low concentrations.

Can I use ACE-1 (Recombinant) as a positive control for Western blot with the matched antibody RP-ACE1?

Yes — that is the primary design intent of this pairing. Load 20–50 ng of ACE-1 (Recombinant) per lane alongside your cell lysate samples. At this amount, RP-ACE1 (rabbit polyclonal; /anti-ace-1-rabbit-polyclonal-antibody) reliably detects the glycosylated ectodomain band at ~140–170 kDa. Because RP-ACE1 and REC-ACE1 are produced and validated in the same lab, you avoid the common problem of a recombinant and antibody sourced from different vendors recognizing different epitopes or denatured vs. native forms inconsistently.

How much recombinant ACE-1 (Recombinant) should I load for Western blot, and will it run at the same size as endogenous ACE?

Load 20–50 ng for a clean single-band signal with RP-ACE1 under standard ECL detection. The recombinant ectodomain will run at ~140–170 kDa — overlapping with endogenous, membrane-shed ACE detected in cell lysates expressing the full-length protein. If you need to distinguish them, note that the full-length transmembrane form runs slightly higher (~180 kDa) due to the intact stalk and transmembrane region. The recombinant serves as an unambiguous positive control band to confirm antibody functionality before interpreting endogenous signal in experimental lanes.

How should I store and handle ACE-1 (Recombinant) to preserve activity, and what is its shelf life after thawing?

Store at -20°C in the supplied single-use aliquots (50 mM Tris-HCl pH 7.5, 150 mM NaCl, 10% glycerol, 5 mM CaCl₂). Avoid repeated freeze-thaw cycles — each cycle measurably reduces metallopeptidase activity. Once thawed, keep on ice and use within 4–6 hours; do not refreeze. For dilutions below ~10 nM, add 0.1% BSA (protease-free) to prevent surface adsorption losses. Shelf life is 12 months from date of manufacture when stored correctly at -20°C. Endotoxin is confirmed <0.1 EU/µg by LAL, so the preparation is suitable for cell-based assays without additional depyrogenation steps.

Validation imagery coming soon

Western blot validation figures for REC-ACE1 will be published here as they are produced in-house.

If you would like to see existing validation data for this antibody before publication, request a sample copy.

  • Product Datasheet

    Full specifications, immunogen, validation, and recommended protocols.

    Request PDF →
  • Certificate of Analysis (COA)

    Lot-specific QC report. Available on request for any catalog lot.

    Request COA →
  • Safety Data Sheet (SDS)

    Handling, storage, and disposal guidance per regulatory standards.

    Request SDS →